What Investors Are Missing about Pfizer and Merck
This essay originally appeared in Fortune. With relevance to current life science companies, the ancient Greek physician Hippocrates, often labelled “the father of modern medicine,” advised almost 3,000 years ago “healing is a matter of time, but it is sometimes also a matter of opportunity.” That counsel rings especially true for a pair of ostensibly beleaguered drugmakers, Pfizer and Merck, both of whose stocks have been battered this week despite…